Patents by Inventor Alain B. Schreiber

Alain B. Schreiber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of conditions requiring enhanced oxygen availability of mammalian tissues
    Patent number: 5015663
    Abstract: Disclosed are pharmaceutical compositions containing naphthoic acid derivatives and method of use for enhancing oxygen availability to mammailian tissue.
    Type: Grant
    Filed: March 5, 1990
    Date of Patent: May 14, 1991
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: John T. Suh, Robert G. Pendleton, Charles E. Pendley, II, Kin T. Yu, Paul R. Menard, Alain B. Schreiber
  • Treatment of conditions requiring enhanced oxygen availability to mammalian tissues
    Patent number: 4948582
    Abstract: Disclosed are pharmaceutical compositions containing naphthoic acid derivatives and method of use for enhancing oxygen availability to mammailian tissue.
    Type: Grant
    Filed: May 11, 1989
    Date of Patent: August 14, 1990
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: John T. Suh, Robert G. Pendleton, Charles E. Pendley, II, Kin T. Yu, Paul R. Menard, Alain B. Schreiber
  • Treatment of conditions requiring enhanced oxygen availability to mammalian tissues
    Patent number: 4861795
    Abstract: Disclosed are pharmaceutical compositions containing naphthoic acid derivatives and method of use for enhancing oxygen availability to mammailian tissue.
    Type: Grant
    Filed: June 23, 1988
    Date of Patent: August 29, 1989
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: John T. Suh, Robert G. Pendelton, Charles E. Pendley, II, Kin T. Yu, Paul R. Menard, Alain B. Schreiber
  • Method for determining the presence of malignant cells
    Patent number: 4782015
    Abstract: The present invention is concerned with a method for determining the presence of a malignant condition at a locus of interest. An exfoliative cell specimen obtained from the locus is contacted with an antibody specific for an antigenic site that is usually only found in the specimen when a malignant condition is present. The contact is made under conditions for detectable binding of the antibody to such antigenic site. After contact, the presence of binding of the antibody to the antigenic site is observed. The binding of the antibody is related to the presence of a malignant condition at the locus. The invention finds utility, for example, in the detection of cervical carcinoma.
    Type: Grant
    Filed: March 30, 1984
    Date of Patent: November 1, 1988
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: Anthony C. Allison, Vera Morhenn, Alain B. Schreiber
  • Analogs of transforming and epidermal growth factor fragments for therapy and diagnosis
    Patent number: 4686283
    Abstract: Polypeptides analogs of fragments of TGF.alpha. and EGF are useful as therapeutic and diagnostic agents.
    Type: Grant
    Filed: April 16, 1985
    Date of Patent: August 11, 1987
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: John J. Nestor, Jr., Alain B. Schreiber
  • Etianic acids as antiangiogenics
    Patent number: 4599331
    Abstract: This invention provides a method for inhibiting angiogenesis in mammals. A pharmaceutically acceptable formulation containing a compound of the formula ##STR1## where X.sub.1 X.sub.2 and X.sub.3 are H, C1, or F and X.sub.3 must be H if the substituent of R.sub.1 is .alpha.OH;R.sup.1 is chosen from the group consisting of hydroxyl and hydrogen;R.sub.2 is chosen from the group of alkyloxy or thioalkyls wherein said alkyls have less than 5 carbon atomsR.sub.3 is H or an alkyl having less than 6 carbon atoms, is administered to the mammal having undesirable angiogenesis.The wavy line at C-16 refers to either .alpha. or .beta..
    Type: Grant
    Filed: December 24, 1984
    Date of Patent: July 8, 1986
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: Alain B. Schreiber, William J. Kowalski, Stefan H. Unger